Atopic Dermatitis: New Perspectives on Managing a Chronic Inflammatory Disease

By Robert E. Kalb, MD and Jeffrey M. Weinberg, MD

The goal of this eHealth Source™ activity is to educate clinicians on atopic dermatitis pathoetiology, best practices in patient evaluations, and the clinical profiles of treatment options for moderate-to-severe disease, including a biologic therapy recently approved by the US Food and Drug Administration (FDA). With the overall goal of improving outcomes for patients with moderate-to-severe atopic dermatitis, this educational activity integrates published clinical data and the experience of expert faculty to provide actionable recommendations on individualizing care and improving patient-clinician communication.

• Language: English
• Publisher: Integritas Communications
• Release date: Feb 23, 2018
• ISBN: 9780998419411

Book preview

ATOPIC DERMATITIS

New Perspectives on Managing a Chronic Inflammatory Disease

Robert E. Kalb, MD and Jeffrey M. Weinberg, MD

¶

PRONOUN

© 2017-2018 Integritas Communications.

All rights reserved. No part of this syllabus may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embedded in articles or reviews.

TABLE OF CONTENTS

Faculty: Robert E. Kalb, MD

Jeffrey M. Weinberg, MD

Preamble: Target Audience

Educational Objectives

Statement of Need/Program Overview

References

Physician Accreditation Statement

Physician Credit Designation

Global Contact Information

Instructions to Receive Credit

Fee Information & Refund/Cancellation Policy

Disclosure of Conflicts of Interest

Disclosure of Unlabeled Use

Disclaimer

Chapter 1: Causes and Consequences of Atopic Dermatitis

Outside-In vs Inside-Out Pathoetiology in Atopic Dermatitis

Key Clinical Highlights

References

Chapter 2: Evaluating Patients With Moderate-to-Severe Atopic Dermatitis

Identifying Atopic and Nonatopic Triggers

Assessing Clinical Outcomes in Patients with Diagnosed Atopic Dermatitis

Nonatopic Comorbidities Associated with Atopic Dermatitis

Key Clinical Highlights

References

Chapter 3: Current and Emerging Therapies for Atopic Dermatitis

Traditional Systemic Therapies for Atopic Dermatitis

Newer Targeted Therapies for Moderate-to-Severe Atopic Dermatitis

Key Clinical Highlights

References

Chapter 4: Individualizing Maintenance Therapy for Moderate-to-Severe Atopic Dermatitis

Addressing Comorbid Conditions

Considering Disease Phenotypes

Monitoring Treatment Outcomes With Topical and Systemic Therapies

Key Clinical Highlights

References

Chapter 5: Educating Patients and Improving Adherence

Encouraging Shared Decision-Making

Enhancing Treatment Adherence

Key Clinical Highlights

References

Atopic Dermatitis Clinical Resource Center™: Guidelines

Patient Resources

International Eczema Council

National Eczema Association

Clinical Assessment Tools

Eczema Area and Severity Index (EASI)

Investigator Global Assessment (IGA)

Scoring Atopic Dermatitis (SCORAD)

Management of difficult-to-treat atopic dermatitis.

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.

Translating atopic dermatitis management guidelines into practice for primary care providers.

Persistence of mild to moderate atopic dermatitis.

Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.

Serious complications from Staphylococcal aureus in atopic dermatitis.

Anti-interleukin-31 receptor A antibody for atopic dermatitis.

Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults.

Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.

Eczema and cardiovascular risk factors in 2 US adult population studies.

Childhood atopic dermatitis and warts are associated with increased risk of infection: a US population-based study.

The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey.

CME Posttest

FACULTY

ROBERT E. KALB, MD

Clinical Professor, Department of Dermatology

SUNY at Buffalo School of Medicine and Biomedical Sciences

Buffalo Medical Group, P.C.

Buffalo, New York

Dr. Robert E. Kalb is a Clinical Professor of Dermatology at the State University of New York at Buffalo Jacobs School of Medicine and Biomedical Sciences, where his extensive teaching responsibilities include coordinating the fourth-year medical student dermatology rotation and working with dermatology and family medicine residents on a daily basis. He also chairs the dermatology department in private practice with the Buffalo Medical Group in Buffalo, New York.

Dr. Kalb obtained his medical degree cum laude from Downstate Health Science Center in Brooklyn, New York, in 1982 and then completed his residency in dermatology at the College of Physicians and Surgeons at Columbia University in New York.

Dr. Kalb has conducted numerous clinical trials investigating possible new treatments for psoriasis and other skin disorders. An invited lecturer at local, national, and international meetings, he has authored more than 60 articles in peer-reviewed